ASX:TLXBiotechs
Telix Pharmaceuticals (ASX:TLX) Falls 24% in a Week After FDA Complete Response Letter
Telix Pharmaceuticals (ASX:TLX) saw its share price drop 24% last week following regulatory setbacks. The decline was driven by the FDA's issuance of a Complete Response Letter, highlighting deficiencies in Telix's Biologics License Application for TLX250-CDx. This regulatory challenge necessitates manufacturing and data improvements before resubmission. While the broader market experienced a tech-led downturn, Telix's drop contrasts with this trend, largely reflecting concerns specific to...